On Dec. 3, 2020, Moderna announced in a letter to the editor published in the New England Journal of Medicine reporting that participants in the Phase 1 study of mRNA-1273, its COVID-19 vaccine candidate, retained high levels of neutralizing antibodies through 119 days following first vaccination (90 days following second vaccination). The study was led by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH).

Moderna re-affirmed its expectation of having approximately 20 million doses available in the U.S. by the end of 2020. Additionally, the Company expected to have between 100 million and 125 million doses available globally in the first quarter of 2021, with 85-100 million of those available in the U.S. and 15-25 million of those available outside of the U.S. These expected first quarter doses are inclusive within the 500 million to up to 1 billion doses that the Company expects to manufacture globally in 2021.